DigestionNCT07477223
Beef Versus Whey Protein: The Gut Showdown Self-Experiment
A study testing Beef protein and Chocolate whey protein in people with Digestion, run by Efforia, Inc at 1 site in United States.
Trial summary
Test whether a doctor-formulated protein made from real beef is more digestible than standard whey protein powder. For the first 30 days, participants receive either standard whey protein powder or Equip Protein and track how the gut responds weekly. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Digestion
- What is being tested?
- Beef protein and Chocolate whey protein
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Feb 2026to 6 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Can read and understand English.
- US resident.
- Willing and able to follow the requirements of the protocol.
- Willing to purchase study materials.
Who cannot join
- Individuals with Beef Allergy
- Individuals with Whey Allergy
- Individuals with Dairy Allergy
- Individuals with Serious Digestive Disorders
- Individuals on a Vegan Diet
- Individuals with Chronic Kidney Disease
- Pregnant or Nursing Individuals
- Individuals with Gout
Trial locations and contacts
1 site in 1 country.
About this study
Test whether a doctor-formulated protein made from real beef is more digestible than standard whey protein powder. For the first 30 days, participants receive either standard whey protein powder or Equip Protein and track how the gut responds weekly. At the 30 day mark, all participants receive the standard Equip protein to track differences in digestability.
Read the detailed description
This remotely administered decentralized trial is designed to critically assess the digestive and overall well-being impact of Equip's Prime Protein, a beef-based protein powder, in comparison to standard whey protein. In an era where nutrition claims are often promoted without rigorous testing, Equip is committed to substantiating the benefits of its protein powder through real-world evidence. Over a span of 60 days, this study will employ a cross-over design whereby participants will document their digestive experiences, energy levels, and overall health, providing valuable insights into how each protein source influences gut comfort and tolerability.
Participants in this study will either start with the standard whey protein and transition to Equip's chocolate-flavored beef protein at the halfway mark or use Equip's product from the outset. This methodology allows for a comprehensive comparison between the two protein sources, aiming to offer individuals a clearer understanding of how different proteins affect their gut health. Through daily structured surveys and feedback, participants will not only learn how their bodies respond to each protein type but also contribute to critical data that could potentially elevate the standard of evidence within the supplement industry.
The significance of this study extends beyond individual health, aiming to challenge and reshape the broader nutrition and supplement landscape. Most companies in the supplement industry base their claims on marketing rather than empirical evidence. By conducting this rigorous, real-world study, Equip is holding itself to a standard of scientific accountability and transparency. The findings from this trial will not only inform participants' choices but also aim to advance the entire field towards cleaner, evidence-based nutrition practices. By identifying which protein source better supports digestion and overall comfort, this study stands to make a meaningful impact on public health and industry standards, moving the focus from marketing claims to measurable, scientifically valid outcomes.
More information can be found on the study recruitment page here: https://app.efforia.com/prime-protein-chocolate-gastrointestinal-health/
- Conditions
- Digestion
- Being tested
- Beef protein, Chocolate whey protein
- Keywords
- digestion, gut, bloating
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beef proteinDietary supplement
Original beef protein powder chocolate flavor, manufactured by Equip, packed with 21g of complete protein, plus naturally occurring collagen and gelatin
Chocolate whey proteinDietary supplement
Whey protein isolate is a dairy-derived protein powder containing ≥90% protein by weight, with minimal lactose and fat. The product is provided as a flavored powder and administered orally when mixed with water. The product does not contain added bioactive ingredients beyond standard whey protein isolate.
| Study group | Role | What they receive |
|---|---|---|
| Crossover longitudinal where participants act as their own control - whey arm | Sham comparator | 30 % of participants receive a standard chocolate whey protein, followed by the Equip chocolate beef protein. Receives: Dietary Supplement: Beef protein; Dietary Supplement: Chocolate whey protein |
| Crossover longitudinal where participants act as their own control - beef arm | Experimental | 70 % of participants receive Equip chocolate protein followed by another Equip chocolate protein. Receives: Dietary Supplement: Beef protein |
What is being measured
The primary outcome is the main question the study is designed to answer.
PROMIS® Scale v1.0 - Gastrointestinal Constipation 9a
Outcome Measure Description: Change from baseline in gastrointestinal constipation as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Gastrointestinal Constipation 9a Scale, Version 1.0, which evaluates constipation frequency, severity, and impact over the past 7 days.
Scoring: Each item is scored 1-5; total raw scores are converted to a T-score metric (range ~25-85). Higher scores indicate more severe constipation (worse outcome).
Measured: Change from baseline (Day 1-5) in gastrointestinal constipation at 4 weeks after the start of the intervention (Day 25-35)
PROMIS® Scale v1.0 - Gastrointestinal Belly Pain 5a Survey
Outcome Measure Description: Change from baseline in gastrointestinal belly pain as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Belly Pain 5a Scale, Version 1.0), measuring frequency and intensity of abdominal pain over the past 7 days.
Scoring: Each item scored 1-5; T-score conversion range ~25-80. Higher scores indicate more severe belly pain (worse outcome).
Measured: Change from baseline (Day 1-5) in gastrointestinal belly pain at 4 weeks after the start of the intervention (Day 25-35)
PROMIS® Scale v1.0 - Gastrointestinal Bowel Incontinence 4a Survey
Outcome Measure Description: Change from baseline in gastrointestinal bowel incontinence as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Bowel Incontinence 4a Scale, Version 1.0), evaluating frequency and impact of bowel incontinence over the past 7 days.
Scoring: Each item scored 1-5; T-score conversion range ~25-80. Higher scores indicate more severe bowel incontinence (worse outcome).
Measured: Change from baseline (Day 1-5) in gastrointestinal bowel incontinence at 8 weeks after the start of the intervention (Day 55-65)
PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a
Outcome Measure Description: Change from baseline in gastrointestinal gas and bloating as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Gas and Bloating 13a Scale, Version 1.1), which evaluates frequency and intensity over the past 7 days.
Scoring: Each item scored 1-5; T-score conversion range ~25-85. Higher scores indicate more severe gas and bloating (worse outcome).
Measured: Change from baseline (Day 1-5) in gastrointestinal gas and bloating at 4 weeks after the start of the intervention (Day 25-35)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start6 Feb 2026
- Primary completion6 Jun 2026 (estimated)
- Study completion6 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DigestionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Crossover observational where participants act as their own control
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Efforia, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07477223
- Sponsor's protocol ID
- 47731
- Status last verified
- May 2026
- First submitted
- 24 Feb 2026
- Last updated
- 28 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Beef Versus Whey Protein: The Gut Showdown Self-Experiment
- ClinicalTrials.gov ID
- NCT07477223
- Acronym / sponsor ID
- 47731
- Conditions
- Digestion
- Keywords
- digestion, gut, bloating
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Efforia, IncIndustry (pharma, biotech, devices)
- Study start
- 6 Feb 2026 (actual)
- Primary completion
- 6 Jun 2026 (estimated)
- Study completion
- 6 Jun 2026 (estimated)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Test whether a doctor-formulated protein made from real beef is more digestible than standard whey protein powder. For the first 30 days, participants receive either standard whey protein powder or Equip Protein and track how the gut responds weekly. At the 30 day mark, all participants receive the standard Equip protein to track differences in digestability.
Detailed description
This remotely administered decentralized trial is designed to critically assess the digestive and overall well-being impact of Equip's Prime Protein, a beef-based protein powder, in comparison to standard whey protein. In an era where nutrition claims are often promoted without rigorous testing, Equip is committed to substantiating the benefits of its protein powder through real-world evidence. Over a span of 60 days, this study will employ a cross-over design whereby participants will document their digestive experiences, energy levels, and overall health, providing valuable insights into how each protein source influences gut comfort and tolerability.
Participants in this study will either start with the standard whey protein and transition to Equip's chocolate-flavored beef protein at the halfway mark or use Equip's product from the outset. This methodology allows for a comprehensive comparison between the two protein sources, aiming to offer individuals a clearer understanding of how different proteins affect their gut health. Through daily structured surveys and feedback, participants will not only learn how their bodies respond to each protein type but also contribute to critical data that could potentially elevate the standard of evidence within the supplement industry.
The significance of this study extends beyond individual health, aiming to challenge and reshape the broader nutrition and supplement landscape. Most companies in the supplement industry base their claims on marketing rather than empirical evidence. By conducting this rigorous, real-world study, Equip is holding itself to a standard of scientific accountability and transparency. The findings from this trial will not only inform participants' choices but also aim to advance the entire field towards cleaner, evidence-based nutrition practices. By identifying which protein source better supports digestion and overall comfort, this study stands to make a meaningful impact on public health and industry standards, moving the focus from marketing claims to measurable, scientifically valid outcomes.
More information can be found on the study recruitment page here: https://app.efforia.com/prime-protein-chocolate-gastrointestinal-health/
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Crossover observational where participants act as their own control
| Arm | Type | Receives |
|---|---|---|
| Crossover longitudinal where participants act as their own control - whey arm | Sham comparator | Dietary Supplement: Beef protein, Dietary Supplement: Chocolate whey protein30 % of participants receive a standard chocolate whey protein, followed by the Equip chocolate beef protein. |
| Crossover longitudinal where participants act as their own control - beef arm | Experimental | Dietary Supplement: Beef protein70 % of participants receive Equip chocolate protein followed by another Equip chocolate protein. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Can read and understand English.
- US resident.
- Willing and able to follow the requirements of the protocol.
- Willing to purchase study materials.
Key exclusion criteria (8 listed)
- Individuals with Beef Allergy
- Individuals with Whey Allergy
- Individuals with Dairy Allergy
- Individuals with Serious Digestive Disorders
- Individuals on a Vegan Diet
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beef proteinOriginal beef protein powder chocolate flavor, manufactured by Equip, packed with 21g of complete protein, plus naturally occurring collagen and gelatin | Dietary supplement | Crossover longitudinal where participants act as their own control - beef arm, Crossover longitudinal where participants act as their own control - whey arm |
| Chocolate whey proteinWhey protein isolate is a dairy-derived protein powder containing ≥90% protein by weight, with minimal lactose and fat. The product is provided as a flavored powder and administered orally when mixed with water. The product does not contain added bioactive ingredients beyond standard whey protein isolate. | Dietary supplement | Crossover longitudinal where participants act as their own control - whey arm |
Primary outcome
PROMIS® Scale v1.0 - Gastrointestinal Constipation 9a
Time frame: Change from baseline (Day 1-5) in gastrointestinal constipation at 4 weeks after the start of the intervention (Day 25-35)
Outcome Measure Description: Change from baseline in gastrointestinal constipation as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Gastrointestinal Constipation 9a Scale, Version 1.0, which evaluates constipation frequency, severity, and impact over the past 7 days. Scoring: Each item is scored 1-5; total raw scores are converted to a T-score metric (range ~25-85). Higher scores indicate more severe constipation (worse outcome).
PROMIS® Scale v1.0 - Gastrointestinal Belly Pain 5a Survey
Time frame: Change from baseline (Day 1-5) in gastrointestinal belly pain at 4 weeks after the start of the intervention (Day 25-35)
Outcome Measure Description: Change from baseline in gastrointestinal belly pain as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Belly Pain 5a Scale, Version 1.0), measuring frequency and intensity of abdominal pain over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range ~25-80. Higher scores indicate more severe belly pain (worse outcome).
PROMIS® Scale v1.0 - Gastrointestinal Bowel Incontinence 4a Survey
Time frame: Change from baseline (Day 1-5) in gastrointestinal bowel incontinence at 8 weeks after the start of the intervention (Day 55-65)
Outcome Measure Description: Change from baseline in gastrointestinal bowel incontinence as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Bowel Incontinence 4a Scale, Version 1.0), evaluating frequency and impact of bowel incontinence over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range ~25-80. Higher scores indicate more severe bowel incontinence (worse outcome).
PROMIS Scale v1.1 - Gastrointestinal Gas and Bloating 13a
Time frame: Change from baseline (Day 1-5) in gastrointestinal gas and bloating at 4 weeks after the start of the intervention (Day 25-35)
Outcome Measure Description: Change from baseline in gastrointestinal gas and bloating as assessed by the Patient-Reported Outcomes Measurement Information System® (PROMIS® Gastrointestinal Gas and Bloating 13a Scale, Version 1.1), which evaluates frequency and intensity over the past 7 days. Scoring: Each item scored 1-5; T-score conversion range ~25-85. Higher scores indicate more severe gas and bloating (worse outcome).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Additional information and join instructions on EfforiaLink provided by the sponsor.
Related trials for Digestion
Active, not recruitingObservational study
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
Colitis, Ulcerative
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
Active, not recruitingPhase 3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Not yet recruitingObservational study
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
Primary Biliary Cholangitis (PBC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Beef protein and Chocolate whey protein in people with Digestion, run by Efforia, Inc at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PROMIS® Scale v1.0 - Gastrointestinal Constipation 9a (time frame: Change from baseline (Day 1-5) in gastrointestinal constipation at 4 weeks after the start of the intervention (Day 25-35)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.